186 related articles for article (PubMed ID: 31828273)
21. Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers.
Dolscheid-Pommerich RC; Keyver-Paik M; Hecking T; Kuhn W; Hartmann G; Stoffel-Wagner B; Holdenrieder S
Tumour Biol; 2017 Oct; 39(10):1010428317730246. PubMed ID: 29034816
[TBL] [Abstract][Full Text] [Related]
22. Decreased serum miR-181a is a potential new tool for breast cancer screening.
Guo LJ; Zhang QY
Int J Mol Med; 2012 Sep; 30(3):680-6. PubMed ID: 22692639
[TBL] [Abstract][Full Text] [Related]
23. Potential diagnostic role of circulating MiRNAs in breast cancer: Implications on clinicopathological characters.
Swellam M; El Magdoub HM; Hassan NM; Hefny MM; Sobeih ME
Clin Biochem; 2018 Jun; 56():47-54. PubMed ID: 29679553
[TBL] [Abstract][Full Text] [Related]
24. Circulating microparticles in breast cancer patients: a comparative analysis with established biomarkers.
Toth B; Nieuwland R; Liebhardt S; Ditsch N; Steinig K; Stieber P; Rank A; Göhring P; Thaler CJ; Friese K; Bauerfeind I
Anticancer Res; 2008; 28(2A):1107-12. PubMed ID: 18507061
[TBL] [Abstract][Full Text] [Related]
25. Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer.
Shao Y; Sun X; He Y; Liu C; Liu H
PLoS One; 2015; 10(7):e0133830. PubMed ID: 26207909
[TBL] [Abstract][Full Text] [Related]
26. Activated leukocyte cell adhesion molecule: a novel biomarker for breast cancer.
Kulasingam V; Zheng Y; Soosaipillai A; Leon AE; Gion M; Diamandis EP
Int J Cancer; 2009 Jul; 125(1):9-14. PubMed ID: 19322904
[TBL] [Abstract][Full Text] [Related]
27. The prognostic significance of preoperative tumor marker (CEA, CA15-3) elevation in breast cancer patients: data from the Korean Breast Cancer Society Registry.
Nam SE; Lim W; Jeong J; Lee S; Choi J; Park H; Jung YS; Jung SP; Bae SY
Breast Cancer Res Treat; 2019 Oct; 177(3):669-678. PubMed ID: 31312932
[TBL] [Abstract][Full Text] [Related]
28. [Long non-coding RNA HOTAIR in plasma as a potential biomarker for breast cancer diagnosis].
Zhang KJ; Zhang Y; Luo ZL; Liu L; Yang J; Wu LC; Yu SS; Liu JB
Nan Fang Yi Ke Da Xue Xue Bao; 2016 Apr; 36(4):488-92. PubMed ID: 27113175
[TBL] [Abstract][Full Text] [Related]
29. Down-regulation of miRNA-30a in human plasma is a novel marker for breast cancer.
Zeng RC; Zhang W; Yan XQ; Ye ZQ; Chen ED; Huang DP; Zhang XH; Huang GL
Med Oncol; 2013 Mar; 30(1):477. PubMed ID: 23389917
[TBL] [Abstract][Full Text] [Related]
30. A circulating miRNA signature as a diagnostic biomarker for non-invasive early detection of breast cancer.
Zhang L; Xu Y; Jin X; Wang Z; Wu Y; Zhao D; Chen G; Li D; Wang X; Cao H; Xie Y; Liang Z
Breast Cancer Res Treat; 2015 Nov; 154(2):423-34. PubMed ID: 26476723
[TBL] [Abstract][Full Text] [Related]
31. Early detection breast cancer: role of circulating plasma miRNA-21 expression as a potential screening biomarker.
Diansyah MN; Prayogo AA; Sedana MP; Savitri M; Zaky Romadhon P; Niken Ayu Amrita P; Yasmin Wijaya A; May Hendrata W; Yudho Bintoro U
Turk J Med Sci; 2021 Apr; 51(2):562-569. PubMed ID: 32950048
[TBL] [Abstract][Full Text] [Related]
32. The diagnostic role of microRNA-34a in breast cancer: a systematic review and meta-analysis.
Imani S; Zhang X; Hosseinifard H; Fu S; Fu J
Oncotarget; 2017 Apr; 8(14):23177-23187. PubMed ID: 28423566
[TBL] [Abstract][Full Text] [Related]
33. Use of CA15-3, CEA and prolactin for the primary diagnosis of breast cancer and correlation with the prognostic factors at the time of initial diagnosis.
Arslan N; Serdar M; Deveci S; Ozturk B; Narin Y; Ilgan S; Ozturk E; Ozguven MA
Ann Nucl Med; 2000 Oct; 14(5):395-9. PubMed ID: 11108173
[TBL] [Abstract][Full Text] [Related]
34. Combined detection of plasma miR-127-3p and HE4 improves the diagnostic efficacy of breast cancer.
Lu M; Ju S; Shen X; Wang X; Jing R; Yang C; Chu H; Cong H
Cancer Biomark; 2017; 18(2):143-148. PubMed ID: 27983524
[TBL] [Abstract][Full Text] [Related]
35. Clinical Significance of let-7a-5p and miR-21-5p in Patients with Breast Cancer.
Chen C; Liu X; Chen C; Chen Q; Dong Y; Hou B
Ann Clin Lab Sci; 2019 May; 49(3):302-308. PubMed ID: 31308028
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of Serum Integrin αvβ3 & Vitronectin in the Early Diagnosis of Breast Cancer.
Radwan AF; Ismael OE; Fawzy A; El-Mesallamy HO
Clin Lab; 2019 Jul; 65(7):. PubMed ID: 31307158
[TBL] [Abstract][Full Text] [Related]
37. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
38. Elevated serum CA15-3 levels correlate with positive estrogen receptor and initial favorable outcome in patients who died from recurrent breast cancer.
Nishimura R; Nagao K; Miyayama H; Matsuda M; Baba K; Matsuoka Y; Yamashita H
Breast Cancer; 2003; 10(3):220-7. PubMed ID: 12955034
[TBL] [Abstract][Full Text] [Related]
39. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P
BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247
[TBL] [Abstract][Full Text] [Related]
40. An updated evaluation of serum sHER2, CA15.3, and CEA levels as biomarkers for the response of patients with metastatic breast cancer to trastuzumab-based therapies.
Perrier A; Boelle PY; Chrétien Y; Gligorov J; Lotz JP; Brault D; Comperat E; Lefèvre G; Boissan M
PLoS One; 2020; 15(1):e0227356. PubMed ID: 31910438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
